Clinical Trials Logo

Peripheral Vascular Diseases clinical trials

View clinical trials related to Peripheral Vascular Diseases.

Filter by:

NCT ID: NCT03490968 Completed - Clinical trials for Peripheral Arterial Disease

The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD

Start date: May 22, 2018
Phase: N/A
Study type: Interventional

Test the theory that abnormalities in the large blood vessels that deliver blood to your leg and the very small blood vessels in your leg's muscles (invisible to the eye) work together to worsen your leg function and walking.

NCT ID: NCT03478085 Completed - Clinical trials for Peripheral Arterial Disease

Near-Infrared Spectroscopy-Guided Exercise Training in Peripheral Arterial Disease

Start date: June 1, 2013
Phase: Early Phase 1
Study type: Interventional

Background: Patients suffering with atherosclerotic peripheral arterial disease (PAD) have limited therapeutic options to improve claudication. Supervised exercise programs are generally effective in improving leg pain from walking, but are poorly adhered to because of patient discomfort. The benefit of exercise training programs is thought to be mediated in part through repeated ischemic stimuli that activate endogenous regenerative mechanisms. In preliminary studies, exercise-induced tissue desaturation by near infrared spectroscopy (NIRS) precedes the onset of leg pain. This proposal aims to explore a novel strategy of exercise training in PAD based on measured tissue hypoxia rather than pain symptoms using NIRS to non-invasively characterize muscle oxygen tension. Methods: In subjects with symptomatic peripheral arterial disease, the efficacy of a novel NIRS-based strategy of thrice-weekly exercise training will be assessed. Enrolled subjects will be randomized to NIRS-based training, traditional claudication-based training, or self-directed walking. The hypotheses tested include: 1) NIRS-directed exercise improves claudication to a similar degree as symptom-directed exercise training and 2) is superior to self-directed walking. In the symptom-based group, physical effort will be dictated by claudication symptoms, whereas in the hypoxia-based training program, physical effort is dictated by NIRS measure of calf oxygen tension. Efficacy in the training programs will be evaluated by total walking time on a standard graded treadmill test after 12 weeks. Other measures will be claudication onset time, subjective and objective measures of physical activity, changes in vascular function. In addition, the hypothesis that hypoxia-directed training will result in increased ischemic signaling and increased progenitor cell mobilization to a degree similar as in claudication-based training will be tested. Conclusions: These experiments will test whether a training strategy based on tissue hypoxia (measured by NIRS) is as effective as and more tolerable than traditional symptom-based training programs in PAD. In addition, these experiments will characterize mechanistic responses to hypoxia that may account for clinical improvements that exercise training affords.

NCT ID: NCT03469349 Completed - Clinical trials for Peripheral Arterial Diseases

Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

APOLLO
Start date: May 1, 2018
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.

NCT ID: NCT03458754 Completed - Clinical trials for Peripheral Arterial Disease

Maximal Exercise Capacity, Physical Activity and Respiratory Muscle Strength in Peripheral Artery Disease

Start date: January 1, 2018
Phase:
Study type: Observational

The primary aim of the study is to evaluate the maximal and submaximal exercise capacity in patients with peripheral artery disease (PAD). The secondary aim of the study is assessment of physical activity level, respiratory function, peripheral and respiratory muscle strength, respiratory muscle endurance, depression, quality of life, intermittent claudication and cardiovascular risk factors in patients with PAD.

NCT ID: NCT03457662 Completed - Clinical trials for Cardiovascular Diseases

Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With PAD and Claudication

SMART-PAD
Start date: March 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to evaluate the safety and efficacy of sonodynamic therapy (SDT) on reducing atherosclerotic plaques inflammation among patients with symptomatic femoropopliteal peripheral artery disease.

NCT ID: NCT03446027 Completed - Clinical trials for Intermittent Claudication

Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients With Intermittent Claudication Compared to Best Available Treatment?

NESIC
Start date: February 16, 2018
Phase: N/A
Study type: Interventional

Intermittent claudication (IC) is caused by a blockage in the artery of the leg, causing muscle pain. Although some evidence of the efficacy of neuromuscular electrical stimulation (NMES) in the management of patients with IC exists, further high quality research is required. This proposed study is vital to identify the contribution of clinical change using NMES, compared to the current gold standard recommended practice of supervised exercise therapy (SET) and, actual standard of care offered in the majority of the UK and Ireland, including best medical therapy (BMT). The device is expected to increase the walking distance in patients with intermittent claudication (IC), and therefore have a benefit on the same when provided in addition to supervised exercise programmes. It is also expected to cause a reduction in pain symptoms and reduced likelihood of major intervention in late stage peripheral arterial disease (PAD). The principal research objective is to assess the clinical efficacy of a neuromuscular electrical stimulation (NMES) device as an adjunct to the local standard care that is available at the study randomisation sites, in order to improve walking distance in patients with intermittent claudication (IC).

NCT ID: NCT03435835 Completed - Clinical trials for Peripheral Arterial Disease

Heat Therapy to Reduce Pain and Improve Walking Tolerance

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether exposure to heat therapy improves calf muscle oxygenation and enhances walking tolerance in patients with symptomatic Peripheral Arterial Disease (PAD).

NCT ID: NCT03424746 Completed - Clinical trials for Peripheral Arterial Disease

Chelation Therapy in Diabetic Patients With Critical Limb Ischemia

TACT-PAD
Start date: August 2015
Phase: Early Phase 1
Study type: Interventional

This is a Pilot Trial Using Chelation Therapy for Limb Preservation in Diabetic Patients with Critical Limb Ischemia.

NCT ID: NCT03414515 Completed - Clinical trials for Peripheral Arterial Disease

Endovascular Treatment of Peripheral Artery Disease (PAD)

Start date: May 2, 2018
Phase:
Study type: Observational

The purpose of this observational study is to evaluate the performance and safety of endovascular treatment with stenting (Optimed Sinus Superflex 635 or Qualimed Pontos-pp) or balloon angioplasty (Cardionovum Legflow or Optimed Nylotrack .035 + .018) according to current practice. The goal of the study will be achieved by assessing binary restenosis with duplex ultrasound, peri- and postoperative complications, technical success, target lesion revascularization, amputation and clinical outcome.

NCT ID: NCT03395236 Completed - Clinical trials for Peripheral Arterial Disease

ILLUMENATE Below-The-Knee (BTK) Arteries: a Post Market Clinical Study

BTK PMS
Start date: April 20, 2018
Phase: Phase 4
Study type: Interventional

The objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the StellarexTM 0.014" OTW Drug-coated Angioplasty Balloon in the treatment of lesions in "below the knee" popliteal (P3 segment) and infra-popliteal arteries according to the Instructions for Use in Rutherford-Becker Classification (RCC) 3, 4 and 5 patient populations. This study will be conducted in Europe across up to 10 centers in up to 75 subjects. Office visits will occur at 30 days, 6, 12, and 24 months post-index procedure.